A pilot study of nasal fentanyl for patient controlled treatment of cancer pain

Journal of Opioid Management

Volumn 10, Issue 1, 2014, Pages 21-28

  Thronaes M ^a,b   Kaasa, S ^a,b   Dale, O ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Fentanyl; Incident pain; Nasal; Neoplasm; Opioids; Pain ladder; Pain relief

Indexed keywords

FENTANYL; MORPHINE; NARCOTIC ANALGESIC AGENT;

11 POINT NUMERIC RATING SCALE; ADULT; AGED; ANALGESIA; ARTICLE; BEHAVIOR DISORDER; CANCER PAIN; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; HEARING DISORDER; HICCUP; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; NAUSEA; NEOPLASM; PATIENT CONTROLLED ANALGESIA; PILOT STUDY; PRURITUS; RATING SCALE; RISK REDUCTION; SEDATION; SUSTAINED DRUG RELEASE; TASTE DISORDER; TELECONSULTATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; VERY ELDERLY; XEROSTOMIA;

ADMINISTRATION, INTRANASAL; AGED; AGED, 80 AND OVER; ANALGESIA, PATIENT-CONTROLLED; ANALGESICS, OPIOID; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PAIN, INTRACTABLE; PILOT PROJECTS;

EID: 84897130382     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2014.0188     Document Type: Article

References (27)

1. WHO: Cancer Pain Relief. Geneva: WHO, 1996.
2. Caraceni A, Hanks G, Kaasa S, et al.: Use of opioid analgesics in the treatment of cancer pain: Evidence-based recommendations from the EAPC. Lancet Oncol. 2012; 13(2): e58-e68.
3. Portenoy RK, Hagen NA: Breakthrough pain: Definition and management. Oncology. 1989; 3(8 suppl): 25-29. (Pubitemid 19224897)
4. Knudsen AK, Brunelli C, Kaasa S, et al.: Which variables are associated with pain intensity and treatment response in advanced cancer patients? - Implications for a future classification system for cancer pain. Eur J Pain. 2011; 15(3): 320-327.
5. Walsh TD, MacDonald N, Bruera E, et al.: A controlled study of sustained-release morphine sulfate tablets in chronic pain from advanced cancer. Am J Clin Oncol. 1992; 15(3): 268-272.
6. Finn JW, Walsh TD, MacDonald N, et al.: Placebo-blinded study of morphine sulfate sustained-release tablets and immediate-release morphine sulfate solution in outpatients with chronic pain due to advanced cancer. J Clin Oncol. 1993; 11(5): 967-972. (Pubitemid 23146095)
7. Young-McCaughan S, Miaskowski C: Definition of and mechanism for opioid-induced sedation. Pain Manag Nurs. 2001; 2(3): 84-97. (Pubitemid 33077261)
8. Redmond M, Glass P: Opiate-induced nausea and vomiting: What is the challenge? Anesth Analg. 2005; 101(5): 1341-1342. (Pubitemid 41531868)
9. Laugsand EA, Kaasa S, de Conno F, et al.: Intensity and treatment of symptoms in 3,030 palliative care patients: A cross-sectional survey of the EAPC Research Network. J Opioid Manag. 2009; 5(1): 11-21.
10. Barnes EA, Bruera E: Fatigue in patients with advanced cancer: A review. Int J Gynecol Cancer. 2002; 12(5): 424-428.
11. Moore P, Dimsdale JE: Opioids, sleep, and cancer-related fatigue. Med Hypotheses. 2002; 58(1): 77-82. (Pubitemid 34136731)
12. Villars P, Dodd M, West C, et al.: Differences in the prevalence and severity of side effects based on type of analgesic prescription in patients with chronic cancer pain. J Pain Symptom Manage. 2007; 33(1): 67-77. (Pubitemid 46017078)
13. Farrar JT, Cleary J, Rauck R, et al.: Oral transmucosal fentanyl citrate: Randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst. 1998; 90(8): 611-616. (Pubitemid 28204805)
14. Christrup LL, Foster D, Popper LD, et al.: Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: A randomized, double-blind, double-dummy, two-way, crossover study. Clin Ther. 2008; 30(3): 469-481. (Pubitemid 351483922)
15. Moksnes K, Fredheim OM, Klepstad P, et al.: Early pharmacokinetics of nasal fentanyl: Is there a significant arterio-venous difference? Eur J Clin Pharmacol. 2008; 64(5): 497-502.
16. Foster D, Upton R, Christrup L, et al.: Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. Ann Pharmacother. 2008; 42(10): 1380-1387.
17. Kress HG, Oronska A, Kaczmarek Z, et al.: Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: A phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther. 2009; 31(6): 1177-1191.
18. Fallon M, Reale C, Davies A, et al.: Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: A multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study. J Support Oncol. 2011; 9(6): 224-231.
19. Passik SD, Kirsh KL: Weighing in on the off-label use of Actiq for noncancer-related pain: A recipe for success or a recipe for disaster? Pain Med. 2007; 8(2): 130-133.
20. Bennett RL, Batenhorst RL, Bivins BA, et al.: Patient-controlled analgesia: A new concept of postoperative pain relief. Ann Surg. 1982; 195(6): 700-705. (Pubitemid 12124217)
21. Hudcova J, McNicol E, Quah C, et al.: Patient controlled opioid analgesia versus conventional opioid analgesia for postoperative pain. Cochrane Database Syst Rev. 2006; (4): CD003348.
22. Michna E, Ross EL, Hynes WL, et al.: Predicting aberrant drug behavior in patients treated for chronic pain: Importance of abuse history. J Pain Symptom Manage. 2004; 28(3): 250-258. (Pubitemid 39158807)
23. Farrar JT, Portenoy RK, Berlin JA, et al.: Defining the clinically important difference in pain outcome measures. Pain. 2000; 88(3): 287-294.
24. Mercadante S, Radbruch L, Davies A, et al.: A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: An open-label, randomised, crossover trial. Curr Med Res Opin. 2009; 25(11): 2805-2815.
25. Cherny N, Ripamonti C, Pereira J, et al.: Strategies to manage the adverse effects of oral morphine: An evidence-based report. J Clin Oncol. 2001; 19(9): 2542-2554. (Pubitemid 32391226)
26. Klepstad P, Kaasa S, Skauge M, et al.: Pain intensity and side effects during titration of morphine to cancer patients using a fixed schedule dose escalation. Acta Anaesthesiol Scand. 2000; 44(6): 656-664. (Pubitemid 30413411)
27. Farrar JT: Advances in clinical research methodology for pain clinical trials. Nat Med. 2010; 16(11): 1284-93.